corticosterone and Central Serous Chorioretinopathy

corticosterone has been researched along with Central Serous Chorioretinopathy in 1 studies

Central Serous Chorioretinopathy: A visual impairment characterized by the accumulation of fluid under the retina through a defect in the retinal pigment epithelium.

Research

Studies (1)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Change in Best Corrected Visual Acuity

Visual acuity will be measured with standard eye charts, with manifest refraction at the initiation and conclusion of treatment. Although an important measure, this was not chosen as the primary outcome measure, as some patients with central serous chorioretinopathy may have a normal visual acuity when properly refracted (refraction can change with elevation of the macula by sub-retinal fluid) (NCT01822561)
Timeframe: Baseline and 1 month after treatment

Change in Macular Thickness

Automated software to calculate the thickness of the macula is standard on commercial OCT devices. Macular thickness before and after treatment will be assessed and compared. (NCT01822561)
Timeframe: Baseline and 1 month after treatment

Change in Serum Potassium

Eplerenone can cause elevation of serum potassium. After initial screening, serum potassium was evaluated at 1 and 4 weeks after baseline. (NCT01822561)
Timeframe: Baseline and 1 month after treatment

Change in Subfoveal Choroidal Thickness, Study Eye

Choroidal thickness can be measured using optical coherence tomography, and is known to be affected in patients with central serous chorioretinopathy. Thickness of the choroid under the fovea will be manually calculated in both the study eye. (NCT01822561)
Timeframe: Baseline and 1 month after treatment

Complete Resolution of Subretinal Fluid

Optical coherence tomography is an imaging technique capable of extremely high resolution (~5-7 microns) imaging of the macula, and is able to detect the presence and amount of subretinal fluid present, the key anatomic abnormality in Central Serous Chorioretinopathy (NCT01822561)
Timeframe: Baseline and 1 month after treatment

Other Studies

1 other study available for corticosterone and Central Serous Chorioretinopathy